142 related articles for article (PubMed ID: 30380950)
1. Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women's Health Initiative study.
Santen RJ; Yue W
Climacteric; 2019 Feb; 22(1):3-12. PubMed ID: 30380950
[TBL] [Abstract][Full Text] [Related]
2. Effects of menopausal hormonal therapy on occult breast tumors.
Santen RJ; Song Y; Yue W; Wang JP; Heitjan DF
J Steroid Biochem Mol Biol; 2013 Sep; 137():150-6. PubMed ID: 23748149
[TBL] [Abstract][Full Text] [Related]
3. Occult breast tumor reservoir: biological properties and clinical significance.
Santen RJ; Yue W; Heitjan DF
Horm Cancer; 2013 Aug; 4(4):195-207. PubMed ID: 23632998
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone therapy and breast cancer.
Santen RJ
J Steroid Biochem Mol Biol; 2014 Jul; 142():52-61. PubMed ID: 23871991
[TBL] [Abstract][Full Text] [Related]
5. The Women's Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context.
Chlebowski RT; Aragaki AK
Menopause; 2023 Apr; 30(4):454-461. PubMed ID: 36727752
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
7. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
Simon JA; Nahum GG; Stanislaw H; Gaines T
Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
[TBL] [Abstract][Full Text] [Related]
8. Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen.
Yue W; Wang J; Atkins KA; Bottalico L; Mesaros C; Blair IA; Santen RJ
Int J Cancer; 2018 Sep; 143(5):1259-1268. PubMed ID: 29577272
[TBL] [Abstract][Full Text] [Related]
9. Recent epidemiological evidence relevant to the clinical management of the menopause.
Shapiro S
Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
[TBL] [Abstract][Full Text] [Related]
11. Invited commentary: Postmenopausal unopposed estrogen and breast cancer risk in the Women's Health Initiative--before and beyond.
Linet MS
Am J Epidemiol; 2008 Jun; 167(12):1416-20. PubMed ID: 18448443
[TBL] [Abstract][Full Text] [Related]
12. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
Lemay A
J Obstet Gynaecol Can; 2002 Sep; 24(9):711-5. PubMed ID: 12360366
[TBL] [Abstract][Full Text] [Related]
13. A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis?
Jordan VC
Menopause; 2014 Oct; 21(10):1160-4. PubMed ID: 24618769
[TBL] [Abstract][Full Text] [Related]
14. Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality.
Obiorah I; Jordan VC
Menopause; 2013 Apr; 20(4):372-82. PubMed ID: 23921472
[TBL] [Abstract][Full Text] [Related]
15. Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy.
Santen RJ; Yue W; Heitjan DF
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1038-48. PubMed ID: 22586072
[TBL] [Abstract][Full Text] [Related]
16. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
[TBL] [Abstract][Full Text] [Related]
17. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 2. The Women's Health Initiative: estrogen plus progestogen.
Shapiro S; Farmer RD; Mueck AO; Seaman H; Stevenson JC
J Fam Plann Reprod Health Care; 2011 Jul; 37(3):165-72. PubMed ID: 21642264
[TBL] [Abstract][Full Text] [Related]
18. Issues to debate on the Women's Health Initiative: failure of estrogen plus progestin therapy for prevention of breast cancer risk.
Luukkainen T
Hum Reprod; 2003 Aug; 18(8):1559-61. PubMed ID: 12871861
[TBL] [Abstract][Full Text] [Related]
19. The prevention of breast cancer through reduced ovarian steroid exposure.
Spicer DV; Pike MC
Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study.
Shufelt C; Bairey Merz CN; Pettinger MB; Choi L; Chlebowski R; Crandall CJ; Liu S; Lane D; Prentice R; Manson JE;
Menopause; 2018 Sep; 25(9):985-991. PubMed ID: 29738414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
